Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bris10 M2SR intranasal H3N2 vaccine challenge trial
2017-004971-30Phase 2Completed
- Sponsor
- FluGen
- Start
- Feb 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza and influenza A H3N2 (H3N2) comparing Bris10 M2SR Vaccine with Placebo (2 arms). Primary endpoint: Influenza viral shedding AUC by qRT-PCR. Started Feb 2018; status: completed.
02
Drugs
Bris10 M2SR Vaccine
03
Conditions
influenzainfluenza A H3N2 (H3N2)
Beyond the preview
Go deeper on 2017-004971-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004971-30.